As part of the company's push to carve out a share of the $142 billion U.S. drug delivery market, Rainbow Coral Corp. said that it has opened talks this week to potentially partner with an emerging innovator in the transdermal delivery sector. Some analysts have predicted that the transdermal delivery market could be worth as much as $31.5 billion
According to news reporting out of Warangal, India, by NewsRx editors, research stated, "Fast-dissolving drug-delivery systems were first developed in the late 1970 s as an alternative to tablets, capsules, and syrups for pediatric and geriatric patients who experience difficulties swallowing traditional oral solid dosage forms. Our news journalist
As part of the company s push to carve out a share of the $142 billion U.S. drug delivery market, Rainbow Coral Corp. opened talks this week to potentially partner with an emerging innovator in the transdermal delivery sector. RBCC formed a biotech subsidiary, Rainbow BioSciences, to market and develop new medical and research technology innovat
Pre-filled syringes and related devices- discover companies' revenue prospects. How are companies in the pre-filled syringe industry performing? Visiongain's report gives you data, analyses and discussions for producers of those drug delivery devices.
Research and Markets has announced the addition of the "Injectable Drug Delivery Market by Formulations, Devices& Therapeutics- Global Forecasts to 2017" report to its offerings. In a release, Research and Markets noted that report highlights include:. The global injectable drug delivery technologies market was valued at $22.5 billion in 2012, and
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule. "We are very pleased to have the FDA clearance to proceed," stated Nadav Kidron, CEO of Oramed. Oramed...
pSivida Corp., a company focused on developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced financial results for its third quarter ended March 31. "We are very pleased that the FDA has accepted Alimera Sciences' recently resubmitted New Drug Application for ILUVIEN for chronic Diabetic Macular Ede
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Cardiovascular Drug Delivery- Technologies, Markets and Companies" to their offering. Drug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients